Why Durham biotech’s pivot means smaller, leaner company


Precision BioSciences has sold its lead cell therapy asset as the company shifts focus exclusively to gene editing.

Previous Medtronic sales, profits top expectations as demand climbs and cost cuts take effect
Next Worthington Bank taps leader as it expands into Denton